Preclinical data from the Company’s CMX521 program will be featured in a late-breaking oral presentation session at the International Conference on Antiviral Research (ICAR) on Wednesday, March 23, 2022 from 12:15 – 1:00 pm PT. CMX521 was found to significantly reduce lung viral titer and clinical symptoms in a SARS-CoV-2 mouse model.

The state funds will allow READDI to build out a small management team, including the initial hire of a CEO, who will work to create broad spectrum antiviral drugs to combat novel coronaviruses, among other viruses.